JP2024508683A5 - - Google Patents
Info
- Publication number
- JP2024508683A5 JP2024508683A5 JP2023547793A JP2023547793A JP2024508683A5 JP 2024508683 A5 JP2024508683 A5 JP 2024508683A5 JP 2023547793 A JP2023547793 A JP 2023547793A JP 2023547793 A JP2023547793 A JP 2023547793A JP 2024508683 A5 JP2024508683 A5 JP 2024508683A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- fragment
- fusion polynucleotide
- item
- polynucleotide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213919A JP2025026590A (ja) | 2021-03-04 | 2024-12-06 | Ｓｂｉアジュバントを含む組成物及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156860P | 2021-03-04 | 2021-03-04 | |
| US63/156,860 | 2021-03-04 | ||
| PCT/US2022/018610 WO2022187424A1 (en) | 2021-03-04 | 2022-03-03 | Compositions including sbi adjuvants and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213919A Division JP2025026590A (ja) | 2021-03-04 | 2024-12-06 | Ｓｂｉアジュバントを含む組成物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508683A JP2024508683A (ja) | 2024-02-28 |
| JP2024508683A5 true JP2024508683A5 (enExample) | 2024-03-26 |
Family
ID=80820175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547793A Withdrawn JP2024508683A (ja) | 2021-03-04 | 2022-03-03 | Ｓｂｉアジュバントを含む組成物及びその使用方法 |
| JP2024213919A Pending JP2025026590A (ja) | 2021-03-04 | 2024-12-06 | Ｓｂｉアジュバントを含む組成物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213919A Pending JP2025026590A (ja) | 2021-03-04 | 2024-12-06 | Ｓｂｉアジュバントを含む組成物及びその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11771758B2 (enExample) |
| EP (1) | EP4301404A1 (enExample) |
| JP (2) | JP2024508683A (enExample) |
| KR (1) | KR20230154048A (enExample) |
| CN (2) | CN116916950A (enExample) |
| AU (2) | AU2022228575C1 (enExample) |
| BR (1) | BR112023017749A2 (enExample) |
| CA (1) | CA3211083A1 (enExample) |
| IL (2) | IL320523A (enExample) |
| MX (1) | MX2023009995A (enExample) |
| WO (1) | WO2022187424A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060631A1 (en) * | 2017-09-20 | 2019-03-28 | Helix Nanotechnologies, Inc. | EXPRESSION SYSTEMS THAT FACILITATE THE DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE |
| WO2022187424A1 (en) | 2021-03-04 | 2022-09-09 | Helix Nanotechnologies, Inc. | Compositions including sbi adjuvants and methods of use thereof |
| WO2024152844A1 (zh) * | 2023-01-19 | 2024-07-25 | 成都威斯克生物医药有限公司 | 抗SARS-CoV-2奥密克戎突变株及其亚型感染的蛋白及疫苗 |
| US12559515B2 (en) | 2023-12-22 | 2026-02-24 | Helix Nanotechnologies Inc | Cap compounds and RNAS comprising the same |
| US20250270299A1 (en) * | 2024-01-31 | 2025-08-28 | Helix Nanotechnologies Inc | Methods of using compositions comprising sbi domains |
| WO2025166067A1 (en) | 2024-01-31 | 2025-08-07 | Helix Nanotechnologies, Inc. | Sars-cov-2 vaccine compositions and methods |
| WO2026015884A1 (en) | 2024-07-11 | 2026-01-15 | Helix Nanotechnologies Inc | Compositions comprising ire-1 binding sequences and uses thereof |
| WO2026084768A1 (en) | 2024-10-16 | 2026-04-23 | Helix Nanotechnologies Inc | Helper proteins for increased secretion |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485904B1 (en) * | 1997-06-23 | 2002-11-26 | Pfizer, Inc. | DNA encoding a plasminogen activating protein |
| SK782002A3 (en) * | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2002072792A2 (en) * | 2001-03-13 | 2002-09-19 | Corixa Corporation | Heterologous fusion protein constructs comprising a leishmania antigen |
| GB0605735D0 (en) * | 2006-03-22 | 2006-05-03 | Immunobiology Ltd | Composition and method for mediating an immune response |
| GB0610776D0 (en) | 2006-05-31 | 2006-07-12 | Univ Bath | Novel applications for staphylococcus aureus Sbi protein |
| GB201016403D0 (en) | 2010-09-29 | 2010-11-10 | Bath Ventures | Novel interaction between staphylococcus aureus Sbi and C3d protiens |
| SG11201602012RA (en) * | 2013-09-25 | 2016-04-28 | Pronutria Inc | Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof |
| GB201619965D0 (en) | 2016-11-25 | 2017-01-11 | Univ Of Bath The | Immunogenic compositions comprising sbi protein and uses thereof |
| CN110168090B (zh) * | 2016-12-27 | 2023-07-18 | 国立大学法人东京大学 | mRNA的功能化方法 |
| MA54192A (fr) * | 2018-11-07 | 2021-09-15 | Modernatx Inc | Vaccins à arn contre le cancer |
| US20220280633A1 (en) * | 2019-07-30 | 2022-09-08 | Verndari, Inc. | Virus-like particle vaccines |
| KR20230039607A (ko) * | 2020-05-06 | 2023-03-21 | 징코 바이오웍스, 인크. | 변이체 SARS-CoV-2 단백질 및 그의 용도 |
| WO2022187424A1 (en) | 2021-03-04 | 2022-09-09 | Helix Nanotechnologies, Inc. | Compositions including sbi adjuvants and methods of use thereof |
-
2022
- 2022-03-03 WO PCT/US2022/018610 patent/WO2022187424A1/en not_active Ceased
- 2022-03-03 MX MX2023009995A patent/MX2023009995A/es unknown
- 2022-03-03 JP JP2023547793A patent/JP2024508683A/ja not_active Withdrawn
- 2022-03-03 AU AU2022228575A patent/AU2022228575C1/en active Active
- 2022-03-03 EP EP22711777.7A patent/EP4301404A1/en active Pending
- 2022-03-03 KR KR1020237033198A patent/KR20230154048A/ko active Pending
- 2022-03-03 BR BR112023017749A patent/BR112023017749A2/pt unknown
- 2022-03-03 CN CN202280016257.9A patent/CN116916950A/zh active Pending
- 2022-03-03 CN CN202411062411.3A patent/CN119161490A/zh active Pending
- 2022-03-03 US US17/685,717 patent/US11771758B2/en active Active
- 2022-03-03 IL IL320523A patent/IL320523A/en unknown
- 2022-03-03 IL IL305333A patent/IL305333B2/en unknown
- 2022-03-03 CA CA3211083A patent/CA3211083A1/en active Pending
-
2023
- 2023-08-18 US US18/235,464 patent/US12343392B2/en active Active
-
2024
- 2024-12-06 JP JP2024213919A patent/JP2025026590A/ja active Pending
-
2025
- 2025-05-27 US US19/218,897 patent/US20260061048A1/en active Pending
- 2025-07-02 AU AU2025205053A patent/AU2025205053A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11229694B2 (en) | Vaccine against RSV | |
| JP2023513720A5 (enExample) | ||
| EP1053325B1 (en) | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination | |
| JP2023179436A5 (enExample) | ||
| JP2023518596A5 (enExample) | ||
| JP2008529558A5 (enExample) | ||
| WO2020234300A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| JP2011530599A5 (enExample) | ||
| JP2018509935A5 (enExample) | ||
| JP2012501959A5 (enExample) | ||
| JP2013501038A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| CA2408328A1 (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
| JP2014518061A (ja) | ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質 | |
| JP2024522385A5 (enExample) | ||
| RU2014135053A (ru) | Иммуногены для вакцинации против вич | |
| JP2023545707A5 (enExample) | ||
| BR112015013387B1 (pt) | Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas | |
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| JP2024513559A5 (enExample) | ||
| JP2025521082A5 (enExample) | ||
| KR20230084478A (ko) | 면역원성 코로나 바이러스 융합 단백질 및 관련 방법 | |
| JP2025519475A5 (enExample) | ||
| RU2023124900A (ru) | Композиции, содержащие адъюванты sbi, и способы их применения | |
| JP2008531463A5 (enExample) |